Visipaque shortage — IE supply status & alternatives

Visipaque

—

🇦🇺 AUST R 49594 · GE Healthcare Australia Pty Ltd

In supply · Australia

In supply · 🇦🇺 Australia · short in🇪🇸 ES🇮🇪 IE

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Marketing-authorisation holders
Active ingredient (INN)	Visipaque
Therapeutic category	Auto-created by Agencia Española de Medicamentos — Problemas de Suministro scraper
Controlled substance	No

Registrations on file	20

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 2 resolved events

◷

1–2 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇪🇸

Spain

AEMPS · 2d ago

Medium

🇮🇪

Ireland

HPRA · 1mo ago

Medium

Recalls official enforcement reports

🇮🇹

Visipaque

GE Healthcare S.r.l. · Mar 2026

Class ?details ↗

Verified timeline regulator events

🇪🇸 15 June 2026

medium reported

🇪🇸 19 May 2026

Shortage resolved

🇪🇸 16 Apr 2026

Shortage resolved

🇮🇪 26 Mar 2026

medium reported

Sources official regulators

🇪🇸

AEMPS

verified 2d ago

verify ↗

🇮🇪

HPRA

verified 1mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders20 registrations · 4 MA holders

Product	Strength	Form	Market	MA holder	Status
VISIPAQUE INJECTION 270 MG I/ML	270 MG	injection	🇬🇧 GB	GE Healthcare AS	Active
VISIPAQUE INJECTION 320MG I/ML	320MG	injection	🇬🇧 GB	GE Healthcare AS	Active
VISIPAQUE iodixanol	32.6g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	65.2g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	97.8g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	130.4g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	27.5g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	55g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	82.5g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	110g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	5.5g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	11.0g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	6.5g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	13.0g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active
VISIPAQUE iodixanol	22.0g	—	🇦🇺 AU	GE Healthcare Australia Pty Ltd	Active

+5 more registrations on file

Mederti Drug Report

Generated 4 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.